^
    Back
    Association details:
    Biomarker:UGT1A1 mutation
    Cancer:Colorectal Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

    Excerpt:
    ...RAS/BRAF mutation status and UGT1A1*28/*6 gene polymorphism typing should be determined before enrollment....
    Trial ID:
    NCT05969899
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Manag Res
    Title:

    Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only

    Published date:
    04/23/2022
    Excerpt:
    All patients with PC-only CRC were treated with first-line bevacizumab and FOLFIRI, and the irinotecan dose escalation depended on UGT1A1 polymorphism. Patients with PC-only CRC had a median progression-free survival (mPFS) of 18.0 months and a median overall survival (mOS) of 24.6 months.
    Secondary therapy:
    FOLFIRI + irinotecan
    DOI:
    10.2147/CMAR.S355318